- Parents of children suffering from Duchenne Muscular Dystrophy call for the FDA to accelerate its review of Sarepta Therapeutics' (SRPT) eteplirsen. Through their "The Race to Yes" campaign, they plan to petition the White House for a response to the issue. As of March 18, they have 43,750 of the required 100,000 signatures they need by the March 29 deadline.
- SRPT shares plunged 64% on November 12 when the FDA notified the company not to seek accelerated approval.
at Zacks.com (Nov 13, 2014)